SC
PMN icon

Scotia Capital’s ProMIS Neurosciences PMN Stock Holding History

Scotia Capital’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-485
Closed -$5.15K – 947
2025
Q3 		$5.15K Hold
485
– – ﹤0.01% 905
2025
Q2 		$5.86K Hold
485
– – ﹤0.01% 859
2025
Q1 		$8.41K Hold
485
– – ﹤0.01% 842
2024
Q4 		$11.5K Hold
485
– – ﹤0.01% 852
2024
Q3 		$15.1K Buy
+485
New +$18.1K ﹤0.01% 826

Other funds holding PMN

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
DEM
Disciplined Equity Management Neptune Beach, Florida $199M AUM 20.69% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Scotia Capital's PMN Position: Q4 2025 in Review

Scotia Capital sold out of ProMIS Neurosciences (PMN) in Q4 2025, closing a stake of 485 shares — an estimated $5.15K sold.

Scotia Capital first reported a position in PMN in Q3 2024 and held it in 5 quarters. The position peaked at $15.1K in Q3 2024. 9 funds tracked by Wall St. Rank hold PMN as of Q4 2025.

  • Scotia Capital reported no remaining ProMIS Neurosciences position as of Q4 2025 after selling out during the quarter.
  • Scotia Capital sold 485 ProMIS Neurosciences shares in Q4 2025, an estimated $5.15K.
  • Scotia Capital first reported a position in ProMIS Neurosciences in Q3 2024 and held it in 5 quarters.
  • Scotia Capital's ProMIS Neurosciences position peaked at $15.1K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q4 2025.

Based on Scotia Capital's 13F filing for Q4 2025, filed 12 Feb 2026.